Frontiers Case report: Short-term eculizumab use in atypical HUS
Por um escritor misterioso
Descrição
Frontiers Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report
Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future
Frontiers Case report: Eculizumab plus obinutuzumab induction in a deceased donor kidney transplant recipient with DEAP-HUS
PDF) Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity
Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome - ScienceDirect
PDF) Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Frontiers Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
PDF) Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
PDF) Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease
PDF) Deleterious Impact of a Novel CFH Splice Site Variant in Atypical Hemolytic Uremic Syndrome
